Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $127.8 billion by market cap.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and DHR definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the diagnostics & research industry. DHR’s competitive strengths come from its portfolio of high-margin, mission-critical tools in biotech, diagnostics, and life sciences. Strong positions in regulated, R&D-heavy markets give it pricing power and resilience, even in downturns.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Despite its notable strength, DHR shares slipped 25.6% from their 52-week high of $242.80, achieved on Jan. 22. Over the past three months, DHR stock has declined 13.8%, underperforming the S&P 500 Index’s ($SPX) 10% gains during the same time frame.
www.barchart.comShares of DHR fell 20.7% on a YTD basis and dipped 3.9% over the past 52 weeks, underperforming SPX’s YTD gains of 10.5% and 28.5% returns over the last year.
To confirm the bearish trend, DHR is trading below its 200-day moving average since mid-February. It has been trading below its 50-day moving average since late January, with minor fluctuations.
www.barchart.comOn Apr. 21, DHR shares closed down marginally after reporting its Q1 results. Its adjusted EPS of $2.06 exceeded Wall Street expectations of $1.95. The company’s revenue was $5.95 billion, falling short of Wall Street forecasts of $5.99 billion. DHR expects full-year adjusted EPS in the range of $8.35 to $8.55.
In the competitive arena of diagnostics & research, Revvity, Inc. (RVTY) has taken the lead over DHR, showing resilience with a 4.6% uptick on a YTD basis and 10.8% gains over the past 52 weeks.
Wall Street analysts are bullish on DHR’s prospects. The stock has a consensus “Strong Buy” rating from the 22 analysts covering it, and the mean price target of $242.57 suggests a potential upside of 34.3% from current price levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The Trump Administration Just Gave Unusual Machines a Big Boost Lululemon Stock Has Crashed 60% Over the Past Year, But 1 Ugly Distraction Is Finally Gone Micron Stock Just Joined the Trillion-Dollar Club. Wall Street Says MU Still Has Room to Run. As ARR Swells on AI Tailwinds, CrowdStrike Stock Is a Cash Flow Machine